SCHEMBL1472667

SCHEMBL1472667

CC(C)(C)OC(=O)N1CCC(=C(C(=O)NN)c2ccccc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.49
PKM P14618 1/20 0.49
GPR119 Q8TDV5 1/20 0.45
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
GRM5 P41594 1/20 0.42
GRM1 Q13255 1/20 0.42
NR1H2 P55055 1/20 0.42
STS P08842 1/20 0.42
PARP14 Q460N5 1/20 0.41
KIT P10721 1/20 0.41
USP30 Q70CQ3 1/20 0.41
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
ATM Q13315 1/20 0.40
CCR8 P51685 1/20 0.40
ESRRB O95718 1/20 0.40
ESR1 P03372 1/20 0.40
ESRRA P11474 1/20 0.40
ESRRG P62508 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15494313 0.86 KDM4E (0.49) KDM4EPKMGPR119MEN1KMT2A
SCHEMBL1473022 0.86 KDM4E (0.51) KDM4EPKMGPR119MEN1KMT2A
SCHEMBL15494321 0.86 KDM4E (0.47) KDM4EPKMGPR119MEN1KMT2A
SCHEMBL1472808 0.85 KDM4E (0.47) KDM4EPKMGPR119MEN1KMT2A
SCHEMBL12828742 0.85 KDM4E (0.50) KDM4EPKMGPR119MEN1KMT2A
SCHEMBL12828770 0.81 KDM4E (0.50) KDM4EPKMGPR119MEN1KMT2A
SCHEMBL24621774 0.80 KDM4E (0.53) KDM4EPKMGPR119MEN1KMT2A
SCHEMBL13272026 0.79 KDM4E (0.52) KDM4EPKMGPR119MEN1KMT2A
SCHEMBL1473518 0.78 KDM4E (0.51) KDM4EPKMGPR119MEN1KMT2A
SCHEMBL1473275 0.78 KDM4E (0.51) KDM4EPKMGPR119MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513832-B1 Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides BRISTOL MYERS SQUIBB CO (US) 2014-03-05 EP disclosed
US-7915283-B2 e.g. 1-[4-(1-Phenyl-1-(pyrazinyl)-methylene)-piperidin-1-yl]-2-(4-methoxy-7-pyrazinyl-6-azaindol-3-yl)-ethane-1,2-dione; viricides for prophylaxis of lympadenopathy associated virus; synergystic mixtures with immunomodulators BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-29 US disclosed
US-7915283-B2 e.g. 1-[4-(1-Phenyl-1-(pyrazinyl)-methylene)-piperidin-1-yl]-2-(4-methoxy-7-pyrazinyl-6-azaindol-3-yl)-ethane-1,2-dione; viricides for prophylaxis of lympadenopathy associated virus; synergystic mixtures with immunomodulators BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-29 US disclosed
US-20080188481-A1 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES BRISTOL-MYERS SQUIBB COMPANY 2008-08-07 US disclosed
US-20080188481-A1 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES BRISTOL-MYERS SQUIBB COMPANY 2008-08-07 US disclosed
US-7348337-B2 Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides BRISTOL-MYERS SQUIBB COMPANY (US) 2008-03-25 US disclosed
US-20040186292-A1 Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2004-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188481-A1 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES IDO1, IDO2, INMT KDM4E 111/4885PKM 3253/4885GPR119 1747/4885
US-20040186292-A1 Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides IDO1, IDO2, INMT KDM4E 127/4885PKM 3587/4885GPR119 1868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.